Aarti Drugs FY26 Annual Earnings Summary
3 quarters covered · ₹1,977 Cr revenue · ₹141 Cr PAT · 11.9% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Promise tracking available after 2+ quarters of coverage.
Risks flagged during the year
The salicylic acid plant is still in stabilization; delays in achieving 800 tons/month breakeven could pressure margins.
Q3 FY26 · highChinese dumping persists, pressuring realizations. Management plans to file anti-dumping application by April 2026, but relief may take 6-8 months.
Q4 FY26 · highIf crude remains above $110-120, domestic antibiotic demand may decline due to price sensitivity, impacting volumes.
Q4 FY26 · highWest Asia war caused ammonia shortages in March; further escalation could disrupt key raw material availability.
Q2 FY26 · mediumDomestic demand, especially in antibiotics, remained soft with slight degrowth; recovery expected only from Q4.
Q2 FY26 · mediumManagement acknowledged potential price erosion as new methylamine capacity comes online, which could impact margins.
Q3 FY26 · mediumSalicylic acid plant ramp-up slower than expected due to technology changes and quality parameter adjustments, delaying profitability.
Q3 FY26 · mediumWeaker antibiotic demand reduced overall market pool, leading to lower capacity utilization and margin pressure. Management noted this as a key headwind.
Q3 FY26 · mediumAnalyst raised concern about continued high capex (₹150-200 Cr/year) while new plants are still scaling up. Management defended citing smooth Sikar ramp-up and need for oncology investment.
Q4 FY26 · mediumSalicylic acid production remains shut due to equipment delays and variable losses; restart depends on successful installation and testing.
Q4 FY26 · mediumHigher utilization of the methylamine plant requires commensurate metformin production expansion, which is still underway.
Q2 FY26 · lowVoluntary closure of chlorosulfonation process at Tarapur due to gas leak; though no material impact currently, regulatory delays could affect operations.
What changed through the year
Q2 FY26 · High single-digit value growth in H2 FY26
Management aims for high single-digit value growth in H2 FY26, driven by export demand and new capacities.
Q2 FY26 · 15% EBITDA margin target by end of FY27
Targeting 15% EBITDA margin on a consolidated basis by H2 FY27, driven by ramp-up of new plants and cost efficiencies.
Q2 FY26 · 15-20% revenue growth aspiration for FY27
If salicylic acid ramp-up succeeds, management expects 15-20% revenue growth in FY27.
Q2 FY26 · Capex of ₹150-200 crore in FY26
Total capex for FY26 estimated at ₹150-200 crore, with similar levels expected in FY27 for further expansions.
Q3 FY26 · Volume growth of 12-15% in FY27
Management expects 12-15% volume growth in FY27, driven by new products (salicylic acid, methylamines) and single-digit growth in existing basket.
Q3 FY26 · EBITDA margin recovery to 12-13% near-term, 14-15% steady-state
Management targets EBITDA margin of 12-13% in the near term and 14-15% at steady state, driven by backward integration, export mix, and formulation ramp-up.
Q3 FY26 · Sikar plant utilization to reach 50% by March 2026, 75% next quarter
Sikar facility expected to ramp to 50% utilization in Q4 FY26 and 75% in the subsequent quarter, with full utilization within 12 months.
Q3 FY26 · Capex of ₹150-200 crore per year for next two years
Management guided for annual capex of ₹150-200 crore over the next two years, including oncology product development, brownfield expansions, and energy improvements.
Q4 FY26 · Methylamine plant utilization target 55-60% in Q1 FY27
Management expects to cross 55-60% utilization in the June quarter, with a path to >70% within a year.
Q4 FY26 · Volume growth target of 8-10% for FY27
Management targets 8-10% volume growth, with internal aspirations of 10-15%, supported by new capacities.
Q4 FY26 · EBITDA margin target of 13.5-14% for FY27
Targeting EBITDA margins between 13.5% and 14% for FY27, assuming stable crude prices; without war, target was 14-14.5%.
Q4 FY26 · Capex plan of ₹300-400 crore over 2-3 years
Planned capex for brownfield expansions and formulation capacity, including oncology, over the next 2-3 years.